Articles by Abby Proch

31. Social Media Is Replete With Patient RWD, But How Can Researchers Best Use It? 7/1/2026

    Pistoia Alliance's Thierry Escudier and Aditya Tyagi discuss how social media listening is used in clinical research, how it supports established evidence-generation methods, and how it can become a credible, structured input for drug development.

32. Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder 6/26/2026

    Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.

33. RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short 6/25/2026

    Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.

34. Designing Trials For Disease Modification: Cereno Scientific's Approach To Pulmonary Arterial Hypertension 6/10/2026

    Cereno Scientific’s Rahul Agrawal discusses the scientific and strategic rationale behind extending the company’s Phase 2b study duration and how the company incorporated regulator and patient input.

35. New Primary Endpoint For Tetraplegia Drug Gets Support From Patients And The FDA 6/9/2026

    NervGen CEO Adam Rogers discussed why choosing a hand function endpoint for tetraplegia made sense for patients and how regulators helped guide and support the company's decision.

36. Expanding Access To Cell Therapy Trials Beyond AMCs And Into The Community 6/1/2026

    CEO Paul J. Hastings discusses Nkarta's decision to bring outpatient dosing into the community setting, including how it communicated with the FDA on safety and how the changes will improve patient access. 

37. What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 2026 6/1/2026

    On the heels of ISPOR 2026, discover what relevancy HEOR has in the world of clinical operations.

38. Safety Is The Mantra In Kivu Bioscience's ADC Trials For Solid Tumors 5/29/2026

    Kivu Bioscience CEO Mohit Trikha, Ph.D., contends that safer ADCs enable higher effective dosing and could elicit a better response in solid tumors. In this Q&A, he also discusses how parallel trial execution, global site strategy, and stakeholder collaboration support rapid, data-driven development.

39. Taking On Patient Recruitment From Another Angle — The Payer 5/28/2026

    Medzown CEO Jennifer Carter, MD, discusses the challenge of patient recruitment and how coalescing around clinical care data might be a better “in” for recruitment. 

40. Biotech Ecosystem Helps Advance A New Approach To Inflammation Into Trials 5/26/2026

    BioAegis Therapeutics CEO Susan Levinson, Ph.D., talks about the role of partner and regulatory support in bringing their investigational immunotherapy into the clinic.